DE-RISKING RISK SHARING- ENABLING PAYER-PHARMA INTERACTIONS AND VALUE-BASED CONTRACTING WITH RWE
Author(s)
Speakers: Sebastian Schneeweiss, MD, ScD, Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Jeremy Rassen, ScD, President & Chief Scientific Officer, Aetion, Inc., New York, NY, USA; Sharash Shetty, PhD, Therapeutic Area Director, HEOR, Metabolics, Boehringer Ingelheim, Ridgefield, CT, USA; Adrian Towse, MA, MPhil, Director Emeritus and Senior Research Fellow, Office of Health Economics, London, UK
Presentation Documents
Engaging in value-based contracts continues to be a strategic priority among both payers and biopharmaceutical manufacturers seeking to improve health outcomes while curbing healthcare spending. However, implementation challenges exist to constructing risk-sharing agreements including (a) establishing causality between the biopharmaceutical intervention and relevant outcome (b) transparency and alignment in defining and measuring outcomes (c) sufficient data infrastructure to execute and track outcomes (d) assessing upfront risk due to uncertainty of real-world performance. This education symposium brings together key stakeholders — from health insurers and manufacturers to real-world data analytics providers — to describe the benefits and barriers of value-based payment models and the promising role of rapid-cycle analytics of real-world data to address these challenges. Learning objectives will be supported by illustrative case studies.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA